Circassia brings biotech craze from US to London

By Andrew Griffin
07 Feb 2014

Circassia launched the first large biotechnology IPO in London on Thursday after a run of listings from the sector in the US. The UK company, which hopes to find a cure for cat allergies, is set to raise £175m through the deal.

The US has seen strong activity in the biotechnology sector, with a number of listings including some from European firms. But although Circassia has opted for a UK listing, US investors are still expected to make up much of the demand. 

However, market sentiment has been more patchy recently, ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial

Want to learn more? View subscription options